#METABOLOMICS WORKBENCH nmatulionis_20230907_122351 DATATRACK_ID:4296 STUDY_ID:ST002852 ANALYSIS_ID:AN004672 PROJECT_ID:PR001786
VERSION             	1
CREATED_ON             	September 7, 2023, 1:44 pm
#PROJECT
PR:PROJECT_TITLE                 	MYC is a regulator of androgen receptor inhibition-induced metabolic
PR:PROJECT_TITLE                 	requirements in prostate cancer
PR:PROJECT_SUMMARY               	Advanced prostate cancers are treated with therapies targeting the androgen
PR:PROJECT_SUMMARY               	receptor (AR) signaling pathway. While many tumors initially respond to AR
PR:PROJECT_SUMMARY               	inhibition, nearly all develop resistance. It is critical to understand how
PR:PROJECT_SUMMARY               	prostate tumor cells respond to AR inhibition in order to exploit
PR:PROJECT_SUMMARY               	therapy-induced phenotypes prior to the outgrowth of treatment-resistant
PR:PROJECT_SUMMARY               	disease. Here, we comprehensively characterize the effect of AR blockade on
PR:PROJECT_SUMMARY               	prostate cancer metabolism using transcriptomics, metabolomics and bioenergetics
PR:PROJECT_SUMMARY               	approaches. The metabolic response to AR inhibition is defined by reduced
PR:PROJECT_SUMMARY               	glycolysis, robust elongation of mitochondria, and increased reliance on
PR:PROJECT_SUMMARY               	mitochondrial oxidative metabolism. We establish DRP1 activity and MYC signaling
PR:PROJECT_SUMMARY               	as mediators of AR blockade-induced metabolic phenotypes. Rescuing DRP1
PR:PROJECT_SUMMARY               	phosphorylation after AR inhibition restores mitochondrial fission, while
PR:PROJECT_SUMMARY               	rescuing MYC restores glycolytic activity and prevents sensitivity to complex I
PR:PROJECT_SUMMARY               	inhibition. Our study provides new insight into the regulation of
PR:PROJECT_SUMMARY               	treatment-induced metabolic phenotypes and vulnerabilities in prostate cancer.
PR:INSTITUTE                     	University of California, Los Angeles
PR:DEPARTMENT                    	Biological Chemistry
PR:LABORATORY                    	Heather Christofk
PR:LAST_NAME                     	Matulionis
PR:FIRST_NAME                    	Nedas
PR:ADDRESS                       	615 Charles E Young Dr S, BSRB 354-05
PR:EMAIL                         	nmatulionis@mednet.ucla.edu
PR:PHONE                         	3102060163
#STUDY
ST:STUDY_TITLE                   	MYC is a regulator of androgen receptor inhibition-induced metabolic
ST:STUDY_TITLE                   	requirements in prostate cancer
ST:STUDY_SUMMARY                 	Advanced prostate cancers are treated with therapies targeting the androgen
ST:STUDY_SUMMARY                 	receptor (AR) signaling pathway. While many tumors initially respond to AR
ST:STUDY_SUMMARY                 	inhibition, nearly all develop resistance. It is critical to understand how
ST:STUDY_SUMMARY                 	prostate tumor cells respond to AR inhibition in order to exploit
ST:STUDY_SUMMARY                 	therapy-induced phenotypes prior to the outgrowth of treatment-resistant
ST:STUDY_SUMMARY                 	disease. Here, we comprehensively characterize the effect of AR blockade on
ST:STUDY_SUMMARY                 	prostate cancer metabolism using transcriptomics, metabolomics and bioenergetics
ST:STUDY_SUMMARY                 	approaches. The metabolic response to AR inhibition is defined by reduced
ST:STUDY_SUMMARY                 	glycolysis, robust elongation of mitochondria, and increased reliance on
ST:STUDY_SUMMARY                 	mitochondrial oxidative metabolism. We establish DRP1 activity and MYC signaling
ST:STUDY_SUMMARY                 	as mediators of AR blockade-induced metabolic phenotypes. Rescuing DRP1
ST:STUDY_SUMMARY                 	phosphorylation after AR inhibition restores mitochondrial fission, while
ST:STUDY_SUMMARY                 	rescuing MYC restores glycolytic activity and prevents sensitivity to complex I
ST:STUDY_SUMMARY                 	inhibition. Our study provides new insight into the regulation of
ST:STUDY_SUMMARY                 	treatment-induced metabolic phenotypes and vulnerabilities in prostate cancer.
ST:INSTITUTE                     	University of California, Los Angeles
ST:DEPARTMENT                    	Biological Chemistry
ST:LABORATORY                    	Heather Christofk
ST:LAST_NAME                     	Matulionis
ST:FIRST_NAME                    	Nedas
ST:ADDRESS                       	615 Charles E Young Dr S, BSRB 354-05
ST:EMAIL                         	nmatulionis@mednet.ucla.edu
ST:PHONE                         	3102060163
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:GENOTYPE_STRAIN               	NSG
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	tumor-veh-1-01	Treatment:Vehicle | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-veh-1-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-veh-1-02	Treatment:Vehicle | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-veh-1-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-veh-2-01	Treatment:Vehicle | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-veh-2-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-veh-2-02	Treatment:Vehicle | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-veh-2-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-veh-3-01	Treatment:Vehicle | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-veh-3-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-veh-3-02	Treatment:Vehicle | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-veh-3-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-1-01	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-enzalutamide-1-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-1-02	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-enzalutamide-1-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-2-01	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-enzalutamide-2-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-2-02	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-enzalutamide-2-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-3-01	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-enzalutamide-3-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-3-02	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-enzalutamide-3-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-4-01	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-enzalutamide-4-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-4-02	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-enzalutamide-4-02.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-5-01	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	RAW_FILE_NAME=tumor-enzalutamide-5-01.RAW
SUBJECT_SAMPLE_FACTORS           	-	tumor-enzalutamide-5-02	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	RAW_FILE_NAME=tumor-enzalutamide-5-02.RAW
#COLLECTION
CO:COLLECTION_SUMMARY            	Tumors were collected after 10 days of treatment and prepared for histology,
CO:COLLECTION_SUMMARY            	protein extraction, and metabolite extraction.
CO:SAMPLE_TYPE                   	Prostate
#TREATMENT
TR:TREATMENT_SUMMARY             	7 million 16D cells were implanted subcutaneously with 100 μl Matrigel
TR:TREATMENT_SUMMARY             	(Corning) into NSG mice to form primary tumors. Primary tumors were harvested,
TR:TREATMENT_SUMMARY             	minced, and re-implanted (20 - 80 mg of minced tumor tissue with 100 μl
TR:TREATMENT_SUMMARY             	Matrigel per mouse) into NSG mice. 16D tumor-bearing mice were treated by oral
TR:TREATMENT_SUMMARY             	gavage with 10 mg/kg/day of Enzalutamide in the vehicle (1% carboxymethyl
TR:TREATMENT_SUMMARY             	cellulose, 0.5% Tween 80, and 5% dimethylsulfoxide) or the vehicle only, with a
TR:TREATMENT_SUMMARY             	two-days-on/one-day-off schedule.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	After tumor dissection, a maximum of 30mg of tissue was weighed, snap frozen,
SP:SAMPLEPREP_SUMMARY            	and stored at -80C until metabolite extraction. To extract metabolites,
SP:SAMPLEPREP_SUMMARY            	weighed tumor tissue was added to a bead tube (Thermo Fisher Scientific)
SP:SAMPLEPREP_SUMMARY            	containing 1ml 80% methanol plus 10mM potassium trifluoromethanesulfonate (TMSO)
SP:SAMPLEPREP_SUMMARY            	internal standard on ice. Samples were homogenized for 1 minute at max speed on
SP:SAMPLEPREP_SUMMARY            	a bead homogenizer (Thermo Fisher Scientific). Bead tubes were spun at 17000g at
SP:SAMPLEPREP_SUMMARY            	4C for 10 minutes. The supernatant was transferred to an Eppendorf tube and
SP:SAMPLEPREP_SUMMARY            	spun at 17000g at 4C for 10 minutes. A volume of extraction equivalent to 3mg
SP:SAMPLEPREP_SUMMARY            	of tumor tissue was transferred to an ABC vial (Thermo Fisher Scientific). All
SP:SAMPLEPREP_SUMMARY            	volumes were normalized to 500 µl with 80% methanol containing TMSO internal
SP:SAMPLEPREP_SUMMARY            	standard. 80% MeOH was evaporated from the ABC vials using the EZ-2Elite
SP:SAMPLEPREP_SUMMARY            	evaporator (Genevac) and samples were stored at -80°C until analysis. Dried
SP:SAMPLEPREP_SUMMARY            	metabolites were reconstituted in 100 µL of a 50% acetonitrile (ACN) 50% dH20
SP:SAMPLEPREP_SUMMARY            	solution. Samples were vortexed and spun down for 10 minutes at 17,000g. 70 µL
SP:SAMPLEPREP_SUMMARY            	of the supernatant was then transferred to HPLC glass vials. 10 µL of these
SP:SAMPLEPREP_SUMMARY            	metabolite solutions were injected per analysis.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Samples were run on a Vanquish (Thermo Fisher Scientific) UHPLC system with
CH:CHROMATOGRAPHY_SUMMARY        	mobile phase A (20mM ammonium carbonate, pH 9.7) and mobile phase B (100% ACN)
CH:CHROMATOGRAPHY_SUMMARY        	at a flow rate of 150 µL/min on a SeQuant ZIC-pHILIC Polymeric column (2.1 ×
CH:CHROMATOGRAPHY_SUMMARY        	150 mm 5 μm, EMD Millipore) at 35°C. Separation was achieved with a linear
CH:CHROMATOGRAPHY_SUMMARY        	gradient from 20% A to 80% A in 20 minutes followed by a linear gradient from
CH:CHROMATOGRAPHY_SUMMARY        	80% A to 20% A from 20 minutes to 20.5 minutes. 20% A was then held from 20.5
CH:CHROMATOGRAPHY_SUMMARY        	minutes to 28 minutes.
CH:CHROMATOGRAPHY_TYPE           	HILIC
CH:INSTRUMENT_NAME               	Thermo Vanquish
CH:COLUMN_NAME                   	SeQuant ZIC- pHILIC (150 x 2.1mm,5um)
CH:SOLVENT_A                     	20 mM Ammonium carbonate, pH 9.7
CH:SOLVENT_B                     	100% Acetonitrile
CH:FLOW_GRADIENT                 	Check Summary
CH:FLOW_RATE                     	150 µL/min
CH:COLUMN_TEMPERATURE            	35°C
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:LABORATORY_NAME               	Heather Christofk
AN:OPERATOR_NAME                 	Nedas Matulionis
#MS
MS:INSTRUMENT_NAME               	Thermo Q Exactive Orbitrap
MS:INSTRUMENT_TYPE               	Orbitrap
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	The UHPLC was coupled to a Q-Exactive (Thermo Fisher Scientific) mass analyzer
MS:MS_COMMENTS                   	running in polarity switching mode with spray-voltage=3.2kV, sheath-gas=40,
MS:MS_COMMENTS                   	aux-gas=15, sweep-gas=1, aux-gas-temp=350°C, and capillary-temp=275°C. For
MS:MS_COMMENTS                   	both polarities mass scan settings were kept at full-scan-range=(70-1000),
MS:MS_COMMENTS                   	ms1-resolution=70,000, max-injection-time=250ms, and AGC-target=1E6. MS2 data
MS:MS_COMMENTS                   	was also collected from the top three most abundant singly-charged ions in each
MS:MS_COMMENTS                   	scan with normalized-collision-energy=35. Each of the resulting “.RAW” files
MS:MS_COMMENTS                   	was then centroided and converted into two “.mzXML” files (one for positive
MS:MS_COMMENTS                   	scans and one for negative scans) using msconvert from ProteoWizard12. These
MS:MS_COMMENTS                   	“.mzXML” files were imported into the MZmine 2 software package13. Ion
MS:MS_COMMENTS                   	chromatograms were generated from MS1 spectra via the built-in Automated Data
MS:MS_COMMENTS                   	Analysis Pipeline (ADAP) chromatogram module14 and peaks were detected via the
MS:MS_COMMENTS                   	ADAP wavelets algorithm. Peaks were aligned across all samples via the Random
MS:MS_COMMENTS                   	sample consensus aligner module, gap-filled, and assigned identities using an
MS:MS_COMMENTS                   	exact mass MS1(+/-15ppm) and retention time RT (+/-0.5min) search of our
MS:MS_COMMENTS                   	in-house MS1-RT database. Peak boundaries and identifications were then further
MS:MS_COMMENTS                   	refined by manual curation. Peaks were quantified by area under the curve
MS:MS_COMMENTS                   	integration and exported as CSV files. If stable isotope tracing was used in the
MS:MS_COMMENTS                   	experiment, the peak areas were additionally processed via the R package
MS:MS_COMMENTS                   	AccuCor15 to correct for natural isotope abundance. Peak areas for each sample
MS:MS_COMMENTS                   	were normalized by the measured area of the internal standard
MS:MS_COMMENTS                   	trifluoromethanesulfonate (present in the extraction buffer) and by the number
MS:MS_COMMENTS                   	of cells present in the extracted well.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	Peak Area
MS_METABOLITE_DATA_START
Samples	tumor-enzalutamide-1-01	tumor-enzalutamide-1-02	tumor-enzalutamide-2-01	tumor-enzalutamide-2-02	tumor-enzalutamide-3-01	tumor-enzalutamide-3-02	tumor-enzalutamide-4-01	tumor-enzalutamide-4-02	tumor-enzalutamide-5-01	tumor-enzalutamide-5-02	tumor-veh-1-01	tumor-veh-1-02	tumor-veh-2-01	tumor-veh-2-02	tumor-veh-3-01	tumor-veh-3-02
Factors	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):1	Treatment:Enzalutamide | Technical Replicate (Region of Tumor):2	Treatment:Vehicle | Technical Replicate (Region of Tumor):1	Treatment:Vehicle | Technical Replicate (Region of Tumor):2	Treatment:Vehicle | Technical Replicate (Region of Tumor):1	Treatment:Vehicle | Technical Replicate (Region of Tumor):2	Treatment:Vehicle | Technical Replicate (Region of Tumor):1	Treatment:Vehicle | Technical Replicate (Region of Tumor):2
3-hydroxy-trimethyllysine	1312316.718	647802.298	1292392.066	698006.8246	167884.0447	683301.1378	1711586.998	739687.917	356027.1388	825561.2761	250650.3541	832683.1756	1549524.63	1756604.776	319567.286	266805.1144
5'-methylthioadenosine	4064835.233	2976798.684	5816087.13	4217810.022	6170014.125	3526258.535	7678740.506	3810675.021	5015010.547	6800873.709	864900.6026	1799790.437	2994224.605	3486801.921	3252875.178	3492262.558
acetyl-carnitine	6.08E+08	4.50E+08	1.13E+09	6.67E+08	7.18E+08	6.54E+08	1.26E+09	8.68E+08	7.40E+08	9.22E+08	2.45E+08	3.62E+08	6.81E+08	8.31E+08	4.47E+08	3.82E+08
AIR	1504774.5	1721530.088	1678955.464	1813852.199	1667619.592	1591378.193	1639595.091	1901898.362	1488784.281	1771029.354	470861.9297	940613.6363	1271603.68	1581062.101	1055739.742	1877741.075
alanine	2.90E+07	2.34E+07	3.54E+07	2.52E+07	3.97E+07	2.87E+07	5.34E+07	3.23E+07	3.82E+07	4.95E+07	1.67E+07	1.96E+07	3.60E+07	4.35E+07	4.50E+07	3.73E+07
arginine	6.02E+07	4.17E+07	7.34E+07	5.79E+07	1.02E+08	6.39E+07	8.36E+07	5.43E+07	5.38E+07	6.59E+07	2.10E+07	2.83E+07	4.78E+07	5.32E+07	5.00E+07	4.02E+07
asparagine	1.18E+07	6613895.9	1.47E+07	9077568.528	1.80E+07	1.23E+07	2.21E+07	1.18E+07	1.68E+07	2.14E+07	3110170.765	4265958.409	8474477.925	1.26E+07	1.35E+07	7290741.155
betaine	8.84E+07	1.28E+08	3.20E+08	1.48E+08	9.03E+07	1.09E+08	1.43E+08	1.04E+08	1.26E+08	1.92E+08	9.34E+07	1.05E+08	4.92E+07	9.30E+07	9.75E+07	1.39E+08
carnitine	9.76E+08	8.00E+08	2.10E+09	1.20E+09	1.43E+09	9.84E+08	1.93E+09	1.03E+09	8.29E+08	1.38E+09	2.46E+08	4.42E+08	6.06E+08	9.14E+08	9.43E+08	9.70E+08
CDP-choline	4539646.153	3042834.699	1.01E+07	5286932.496	1.34E+07	6476831.876	1.78E+07	7450382.737	8067363.222	7637937.253	981577.5532	1504770.432	5200458.775	6120016.578	5468865.735	6743871.259
choline	1.98E+08	1.79E+08	3.17E+08	2.08E+08	3.22E+08	2.35E+08	3.64E+08	2.50E+08	2.49E+08	2.94E+08	6.98E+07	8.03E+07	8.42E+07	1.43E+08	1.03E+08	1.62E+08
citrulline	1.42E+07	1.58E+07	1.45E+07	1.04E+07	1.64E+07	1.63E+07	1.02E+07	7912524.719	1.19E+07	1.39E+07	1.36E+07	1.59E+07	1.85E+07	2.08E+07	4.28E+07	2.73E+07
creatine	3.15E+09	2.59E+09	3.38E+09	2.75E+09	2.95E+09	2.59E+09	3.33E+09	2.66E+09	2.84E+09	3.14E+09	1.86E+09	2.46E+09	3.46E+09	3.75E+09	3.82E+09	3.66E+09
creatinine	1.11E+07	8360789.694	1.69E+07	1.03E+07	1.87E+07	1.32E+07	2.11E+07	1.08E+07	1.32E+07	1.82E+07	6359142.641	6147158.581	1.01E+07	1.60E+07	1.26E+07	1.63E+07
cystathionine	9631730.665	5884225.307	1.44E+07	1.06E+07	2.41E+07	7198701.099	1.84E+07	8333992.46	1.38E+07	1.75E+07	2024114.304	5051831.181	1.89E+07	1.59E+07	2.31E+07	5.15E+07
cysteine-glutathione disulfide	1123196.573	1053262.672	1351679.673	1403431.773	2489982.093	1982866.377	902803.8833	1169626.767	1555719.416	1284928.517	1170034.048	845379.047	1225223.595	1869788.029	917883.436	957584.5394
gamma-butyrobetaine	2.38E+07	2.26E+07	3.85E+07	2.05E+07	2.82E+07	2.50E+07	3.51E+07	1.66E+07	1.34E+07	2.14E+07	6631001.649	1.34E+07	1.28E+07	2.03E+07	1.90E+07	1.90E+07
gamma-glutamylcysteine	187058.7627	179131.4502	141783.7557	151129.7203	150255.7917	192385.348	211688.4243	139339.3128	156240.0927	178622.5486	12404.11121	91343.78353	117054.6516	184626.8302	0	146509.9484
glycerophosphocholine	7.38E+08	7.71E+08	1.58E+09	1.24E+09	2.85E+09	1.38E+09	2.12E+09	1.31E+09	1.68E+09	1.95E+09	1.71E+08	2.06E+08	5.56E+08	5.58E+08	3.48E+08	1.08E+09
glycine	3936427.623	2574561.455	4760783.638	3100845.598	7178951.365	3852515.294	5552982.345	3068573.837	3401280.483	4453352.341	2050736.213	2868563.519	5300355.456	8112374.927	6798496.605	6594900.371
kynurenic acid	27107.21095	38268.23742	109428.247	127333.611	120762.1011	181538.8622	148764.9303	101922.3763	70983.3756	100741.0784	12768.40723	7500.910156	118275.9026	107010.4912	2526.980469	130298.7682
kynurenine	466514.1448	296671.493	653876.8824	249736.1479	167122.8073	194185.9563	397697.6268	331029.3587	92261.219	350649.3403	248173.7715	322644.4686	421960.4201	689098.9758	110161.4733	206206.0638
L-2-aminobutyric acid	1419548.284	1138338.969	1678027.594	1543955.188	1898375.376	1082745.11	1373651.516	930554.9756	690221.6034	830897.037	8160964.545	2132841.617	1641428.486	2064455.625	1686786.178	2143099.697
leucine / isoleucine	4.70E+07	3.94E+07	6.98E+07	5.30E+07	8.70E+07	7.40E+07	8.28E+07	5.45E+07	5.14E+07	5.79E+07	2.49E+07	1.59E+07	3.52E+07	5.58E+07	4.39E+07	5.84E+07
lysine	3.62E+07	3.16E+07	5.69E+07	3.89E+07	7.79E+07	5.23E+07	5.89E+07	3.44E+07	4.41E+07	4.80E+07	1.59E+07	2.04E+07	3.10E+07	5.68E+07	4.37E+07	5.82E+07
methionine	2.73E+07	2.50E+07	3.94E+07	3.00E+07	5.99E+07	4.37E+07	3.20E+07	2.45E+07	1.89E+07	2.45E+07	1.37E+07	1.11E+07	1.88E+07	3.13E+07	2.61E+07	3.54E+07
methioninesulfoxide	3861847.559	2748344.2	4377804.095	3585067.284	6878669.881	3430593.559	3250986.409	2047409.455	2094907.178	2558324.036	371578.3461	694585.802	1127758.371	1483866.869	1072537.387	1555352.155
NAD+	5540622.975	3693003.379	8192040.33	5307513.7	8411715.656	4297764.435	1.02E+07	3949958.454	5523746.254	9628978.335	770924.4883	3121451.272	4191589.688	6142301.625	7129242.875	4176312.438
NADP+	539307.6957	315389.2439	901608.7809	491765.2036	803859.8056	387107.7708	892161.7842	406810.6283	495180.76	817449.1538	49046.42919	194445.7727	219594.5091	545440.2252	434576.0352	348062.231
nicotinamide	2.37E+08	2.26E+08	2.73E+08	2.27E+08	3.29E+08	3.39E+08	2.94E+08	3.70E+08	2.45E+08	2.44E+08	1.16E+08	1.21E+08	2.92E+08	2.93E+08	3.13E+08	3.43E+08
N-trimethyllysine	6588826.901	5078466.493	8678801.558	7423019.201	1.89E+07	1.03E+07	1.18E+07	8762414.957	1.22E+07	1.42E+07	4361856.082	4840433.732	7751566.895	1.27E+07	1.55E+07	1.68E+07
ophthalmate	0	0	0	0	19171.4342	0	0	22985.0428	0	0	0	0	0	35517.59583	15493.53882	22856.33011
ornithine	1.10E+07	1.30E+07	1.39E+07	1.26E+07	2.05E+07	2.23E+07	1.72E+07	1.33E+07	1.60E+07	1.94E+07	9402357.457	1.01E+07	1.07E+07	1.85E+07	1.55E+07	2.68E+07
phenylalanine	3.17E+07	2.49E+07	5.24E+07	3.45E+07	6.31E+07	5.27E+07	6.30E+07	3.96E+07	3.36E+07	3.60E+07	1.92E+07	9338889.129	2.50E+07	3.98E+07	3.06E+07	5.00E+07
phosphocholine	1.68E+09	1.16E+09	2.25E+09	1.58E+09	1.50E+09	1.18E+09	2.17E+09	1.44E+09	1.43E+09	1.79E+09	6.43E+08	1.14E+09	1.57E+09	2.06E+09	1.66E+09	1.25E+09
proline	3.12E+08	2.60E+08	4.88E+08	3.32E+08	4.65E+08	3.21E+08	5.82E+08	3.72E+08	4.12E+08	5.22E+08	1.53E+08	2.04E+08	3.15E+08	4.53E+08	4.38E+08	4.25E+08
propionyl-carnitine	2.22E+07	1.18E+07	4.41E+07	2.05E+07	2.47E+07	1.57E+07	3.90E+07	2.19E+07	1.67E+07	2.69E+07	3415354.163	6329496.604	1.01E+07	1.18E+07	1.33E+07	1.25E+07
riboflavin	57112.8626	67509.8161	60437.52423	16278.6595	65483.98956	43995.93629	73210.49248	68139.82483	50319.99499	50639.63216	35794.91305	19490.76765	14878.80413	32792.16403	0	26421.87483
S-adenosyl-methionine	1.08E+07	8168448.943	1.24E+07	1.13E+07	1.90E+07	1.15E+07	1.75E+07	1.24E+07	1.58E+07	1.09E+07	2335164.792	4422128.536	1.01E+07	8559027.319	8805813.087	1.15E+07
serine	1.27E+07	7155330.371	1.58E+07	9855248.415	2.16E+07	1.22E+07	2.20E+07	1.05E+07	1.37E+07	1.65E+07	4138291.701	6008346.943	1.10E+07	1.61E+07	1.68E+07	1.36E+07
threonine	7.10E+07	4.78E+07	1.01E+08	6.52E+07	1.04E+08	6.80E+07	7.55E+07	3.90E+07	3.81E+07	5.12E+07	2.17E+07	3.87E+07	7.05E+07	1.07E+08	1.11E+08	1.02E+08
valine	2.75E+07	2.24E+07	4.31E+07	3.14E+07	5.00E+07	4.04E+07	4.76E+07	3.19E+07	2.87E+07	3.19E+07	1.48E+07	1.03E+07	2.19E+07	3.49E+07	2.61E+07	3.87E+07
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	quantified m/z	retention time, min	PubChem ID
3-hydroxy-trimethyllysine	137.072	4.42	439460
5'-methylthioadenosine	298.097	2.38	439176
acetyl-carnitine	204.123	4.81	7045767
AIR	296.064	7.2	161500
alanine	90.055	7.43	5950
arginine	175.119	12.83	6322
asparagine	133.061	7.82	6267
betaine	118.086	5.02	247
carnitine	162.112	6.41	288
CDP-choline	489.115	8.53	13804
choline	104.107	9.81	305
citrulline	176.103	8.28	9750
creatine	132.077	7.43	586
creatinine	114.066	3.96	588
cystathionine	223.075	9.19	834
cysteine-glutathione disulfide	427.095	9.84	3080690
gamma-butyrobetaine	146.118	6.47	725
gamma-glutamylcysteine	251.07	7.64	123938
glycerophosphocholine	258.11	7.18	657272
glycine	76.039	8.13	750
kynurenic acid	190.05	2.84	3845
kynurenine	209.092	4.67	846
L-2-aminobutyric acid	104.071	6.55	80283
leucine / isoleucine	132.102	4.68	6106
lysine	147.113	12.34	5962
methionine	150.058	5.12	6137
methioninesulfoxide	166.053	6.62	158980
NAD+	664.116	7.78	5892
NADP+	744.083	10.04	5886
nicotinamide	123.055	2.63	936
N-trimethyllysine	189.16	11	440121
ophthalmate	290.135	7.07	7018721
ornithine	133.097	11.26	6262
phenylalanine	166.086	4.22	6140
phosphocholine	184.074	8.18	1014
proline	116.071	6.01	614
propionyl-carnitine	218.139	4.07	107738
riboflavin	377.146	3.09	493570
S-adenosyl-methionine	399.145	8.38	34756
serine	106.05	8.08	5951
threonine	120.066	7.13	6288
valine	118.086	5.76	6287
METABOLITES_END
#END